Hermansen JU, Yin Y, Urban A, Myklebust CV, Karlsen L, Melvold K, Tveita AA, Taskén K, Munthe LA, Tjønnfjord GE, Skånland SS(2023) A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine Cell Death Discov, 9(1), 125 DOI 10.1038/s41420-023-01426-w, PubMed 37055391
Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS(2022) Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines Front Oncol, 12, 1040730 DOI 10.3389/fonc.2022.1040730, PubMed 36523963
Zhang D, Harris HM, Chen J, Judy J, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing E, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Pirooznia M, Skånland SS, Gaglione E, Mhibik M, Underbayev C, Ahn IE, Sun C, Herman SEM, Noviski M, Wiestner A(2023) NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts Blood, 141(13), 1584-1596 DOI 10.1182/blood.2022016934, PubMed 36375120